Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.

Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.

CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025, at 9:45 a.m. ET in NYC.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-cantor-global-healthcare-conference-2025-302540438.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) presenting at the Cantor Global Healthcare Conference 2025?

Nuvalent will present at the conference on Thursday, September 4, 2025, at 9:45 a.m. ET in New York City.

Who will represent Nuvalent at the Cantor Global Healthcare Conference 2025?

James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat.

How can investors access Nuvalent's presentation at the Cantor conference?

Investors can access the live webcast through the Investors section of Nuvalent's website at www.nuvalent.com. The presentation will be archived for 30 days afterward.

What type of company is Nuvalent (NUVL)?

Nuvalent is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for clinically proven kinase targets in cancer.